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Abstract
Linear atrophoderma of Moulin (LAM) is an acquired skin condition that manifests in early childhood and
adolescence. It likely represents a form of cutaneous mosaicism that presents with linear, hyperpigmented and
atrophic lesions appearing on the trunk and limbs. Its clinical appearance varies and may closely resemble that of
atrophoderma of Pasini and Pierini (APP) and linear scleroderma. LAM usually follows a benign course and no
effective treatment options exist. We present a case of a young and healthy patient that developed such lesions on
her upper and lower extremities over 5 years. The initial clinical impression of linear scleroderma was reviewed in
favor of LAM following histological examination of the lesions which revealed no significant inflammatory changes.
LAM remains a rare and possibly under recognized entity with reports confined only to the dermatologic literature.
This case highlights the importance of recognizing LAM and distinguishing it from linear scleroderma given the
significant differences in management and prognosis.
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Background
In 1992, Moulin et al. were the first to describe a seem-
ingly unidentified entity characterized by the presence of
hyperpigmented and atrophic band-like lesions that
closely followed Blaschko’s lines [1]. Two years later,
Baumann et al. identified a similar case and coined the
term “linear atrophoderma of Moulin” [2]. Since then,
several additional cases of LAM have been reported in
the dermatologic literature and have expanded upon the
original definition proposed by Moulin et al.
In general LAM lesions develop in childhood or ado-
lescence, and demonstrate a pattern of cutaneous distri-
bution, atrophy and hyperpigmentation that resemble
those observed in linear scleroderma. Here we present a
case of LAM, highlighting the importance of recognizing
this condition and distinguishing it from linear sclero-
derma, given the significant differences in management
and prognosis.
Case presentation
A 10 year old girl initially presented to our dermatology
clinic with an 8 month history of skin lesions developing
on her right upper limb. The patient was otherwise
healthy with an unremarkable family history and an
unaffected twin sister. According to the patient, the
lesions began as bruise-like discolorations. Physical exam
revealed atrophic, non-sclerotic and band-like hyperpig-
mented plaques on her right forearm and upper arm.
Linear atrophoderma of Moulin and linear scleroderma
as well as atrophoderma of Pasini and Pierini were
considered in the differential diagnosis.
An initial punch biopsy revealed an unremarkable
epidermis save for prominent melanin deposition in the
basal layer. Mild inflammatory changes were also noted
in the specimen with perivascular and focally interstitial
lymphoid infiltrates without any obvious signs of scler-
osis. The patient was diagnosed with atrophoderma of
Moulin. Over the next 5 years, month-long trials of
topical steroids, vitamin D analogues, retinoid and hydro-
quinone were administered without any clinical improve-
ment. At 15 years of age the lesions had coalesced to form
band like hyperpigmented atrophic plaques with promin-
ent veins and clear margins on her forearm, upper arm,
shoulder and right inner thigh (Fig. 1). The lesions were
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asymptomatic except for occasional pruritus and the
patient reported no preceding inflammation or hardening
of the skin. There was no joint involvement. Given the
apparent progression of the disease a repeat biopsy was
performed which revealed unremarkable mild dermal
inflammatory changes with no evidence of dermal scler-
osis or atrophic skin appendages that would support a
diagnosis of localized scleroderma. All laboratory findings
were normal including negative anti-nuclear antibodies.
Correlating the clinical picture with the histological exam-
ination, a diagnosis of LAM was re-established.
Discussion
LAM is a rare disorder with reports published only in
dermatologic literature. The classic cutaneous findings
of LAM most commonly arise during childhood or ado-
lescence and primarily affect the trunk and limbs. These
pigmented and atrophic band-like lesions follow the
lines of Blaschko and develop over a finite time period
after which they cease to progress though new lesions
may still develop. Typically, the lesions develop without
preceding inflammation and are devoid of subsequent
induration or sclerosis. However, Browne and Fisher have
reported 2 cases of LAM preceded by a clinical and histo-
logic inflammatory phase and have proposed that the dis-
ease has inflammatory and non-inflammatory variants [3].
Histologically, LAM is characterized by hyperpigmen-
tation of the basal cells along with slight thickening of
the collagen fibers in the dermis and a sparse perivascu-
lar lymphocytic infiltrate. No clear signs of dermal atrophy
are typically seen on histologic examination of routine
LAM specimens. Rather, the atrophic appearance on clin-
ical exam is likely secondary to a reduction in subcutane-
ous tissue which has been demonstrated by ultrasound
imaging [4]. In contrast, microscopic examination of
linear scleroderma lesions reveals thickened and closely
packed collagen bundles accompanied by the hallmark
finding of atrophic eccrine glands, hair follicles and peri-
appendageal fat. It should be mentioned that Atropho-
derma of Pasini and Pierini clinically and histologically
resembles LAM except that it does not adhere to
Blaschko’s lines.
Clinically, LAM is an important entity to consider in
the differential diagnosis of linear scleroderma. This sub-
type of morphea, mainly seen in children and adoles-
cents, presents with linear streaks that typically involve
the limbs or trunk [5]. The lesions eventually evolve into
atrophic and hyperpigmented bands that may become
difficult to distinguish from the lesions seen in LAM.
However, the preceding inflammation, sclerosis and in-
duration that accompany linear scleroderma appear to
be absent in LAM.
Like many other diseases that follow Blaschko’s lines,
LAM is postulated to result from somatic mosaicism
whereby a mutation in early embryogenesis gives rise to
two or more genetically distinct cell populations in the
same individual [6]. This mosaic state with disease likely
resulting from subsequent exposure to an initiating trig-
ger may also represent the underlying pathogenesis of lin-
ear scleroderma. The exact post-zygotic mutation(s) and
secondary events that give rise to the cutaneous changes
associated with LAM and linear scleroderma are still
Fig. 1 A photograph of the entire right upper extremity highlighting
the extent of skin involvement
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unknown and the nosological relationship between LAM,
linear scleroderma and APP remains to be determined.
Thus far, no effective treatment options have been dis-
covered for LAM. High-dose penicillin, topical steroids,
heparin and oral potassium benzoate have all been tried
without success [6]. Recently, methotrexate was reported
to partially improve the clinical appearance of wide-
spread LAM in a 20 year old female [7]. However, its
true effectiveness still remains to be ascertained. In con-
trast, the lesions of linear scleroderma are routinely
treated with systemic steroids and methotrexate with
measurable clinical improvement [8]. This therapeutic
distinction is important as LAM is a benign self-limited
disorder, confined to the skin, with mainly cosmetic con-
cern whereas linear scleroderma may extend beyond the
skin and affect the underlying muscle and bone. Conse-
quently, unlike linear scleroderma, LAM lesions that
overly joints are not worrisome as they do not lead to
joint contractures due to the lack of sclerosis and subse-
quent tightening of overlying tissues.
Conclusions
In conclusion, we believe that LAM is an underrecog-
nized disease that can easily be confused with other
entities showing similar patterns of distribution, atrophy
and hyperpigmentation. Accordingly, rheumatologists
and dermatologists alike should be aware of the overlap-
ping clinical features that are likely to be seen in typical
and atypical manifestations of either disease. Some have
even suggested that LAM, linear scleroderma and APP
may represent a spectrum of disorders rather than unique
entities [9]. While this remains to be validated, the vast
differences in prognosis and treatment warrant firm diag-
noses based on clinical and histological data.
Consent
At the time that patient signed the consent she was 16
years old and in our province of quebec the legal age for
consent is 16, presently she is 18.
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